vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and B&G Foods, Inc. (BGS). Click either name above to swap in a different company.
B&G Foods, Inc. is the larger business by last-quarter revenue ($439.3M vs $284.0M, roughly 1.5× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -4.4%, a 100.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -4.7%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -12.8%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
B&G Foods, Inc. is an American branded foods holding company based in Parsippany, New Jersey. The company was formed in 1996 to acquire Bloch & Guggenheimer, a Manhattan-based producer of pickles, relish and condiments which had been founded in 1889.
ACAD vs BGS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $439.3M |
| Net Profit | $273.6M | $-19.1M |
| Gross Margin | 90.8% | 22.5% |
| Operating Margin | 6.1% | 2.5% |
| Net Margin | 96.3% | -4.4% |
| Revenue YoY | 9.4% | -4.7% |
| Net Profit YoY | 90.3% | -356.5% |
| EPS (diluted) | $1.61 | $-0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | — | ||
| Q3 25 | $278.6M | $439.3M | ||
| Q2 25 | $264.6M | $424.4M | ||
| Q1 25 | $244.3M | $425.4M | ||
| Q4 24 | $259.6M | $551.6M | ||
| Q3 24 | $250.4M | $461.1M | ||
| Q2 24 | $242.0M | $444.6M | ||
| Q1 24 | $205.8M | $475.2M |
| Q4 25 | $273.6M | — | ||
| Q3 25 | $71.8M | $-19.1M | ||
| Q2 25 | $26.7M | $-9.8M | ||
| Q1 25 | $19.0M | $835.0K | ||
| Q4 24 | $143.7M | $-222.4M | ||
| Q3 24 | $32.8M | $7.5M | ||
| Q2 24 | $33.4M | $3.9M | ||
| Q1 24 | $16.6M | $-40.2M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | 22.5% | ||
| Q2 25 | 92.2% | 20.5% | ||
| Q1 25 | 91.7% | 21.2% | ||
| Q4 24 | 91.6% | 21.5% | ||
| Q3 24 | 92.5% | 22.2% | ||
| Q2 24 | 92.5% | 20.7% | ||
| Q1 24 | 88.8% | 22.9% |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | 2.5% | ||
| Q2 25 | 12.2% | 5.2% | ||
| Q1 25 | 7.9% | 8.4% | ||
| Q4 24 | 59.1% | -46.6% | ||
| Q3 24 | 12.6% | 11.1% | ||
| Q2 24 | 12.6% | 9.9% | ||
| Q1 24 | 7.4% | -3.3% |
| Q4 25 | 96.3% | — | ||
| Q3 25 | 25.8% | -4.4% | ||
| Q2 25 | 10.1% | -2.3% | ||
| Q1 25 | 7.8% | 0.2% | ||
| Q4 24 | 55.4% | -40.3% | ||
| Q3 24 | 13.1% | 1.6% | ||
| Q2 24 | 13.8% | 0.9% | ||
| Q1 24 | 8.0% | -8.5% |
| Q4 25 | $1.61 | — | ||
| Q3 25 | $0.42 | $-0.24 | ||
| Q2 25 | $0.16 | $-0.12 | ||
| Q1 25 | $0.11 | $0.01 | ||
| Q4 24 | $0.86 | $-2.81 | ||
| Q3 24 | $0.20 | $0.09 | ||
| Q2 24 | $0.20 | $0.05 | ||
| Q1 24 | $0.10 | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $60.9M |
| Total DebtLower is stronger | — | $2.0B |
| Stockholders' EquityBook value | $1.2B | $470.7M |
| Total Assets | $1.6B | $2.9B |
| Debt / EquityLower = less leverage | — | 4.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | $60.9M | ||
| Q2 25 | $253.6M | $54.1M | ||
| Q1 25 | $217.7M | $61.2M | ||
| Q4 24 | $319.6M | $50.6M | ||
| Q3 24 | $155.1M | $54.7M | ||
| Q2 24 | $177.1M | $40.3M | ||
| Q1 24 | $204.7M | $42.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $917.3M | $470.7M | ||
| Q2 25 | $822.4M | $501.4M | ||
| Q1 25 | $765.2M | $513.1M | ||
| Q4 24 | $732.8M | $524.8M | ||
| Q3 24 | $577.2M | $755.3M | ||
| Q2 24 | $516.7M | $765.0M | ||
| Q1 24 | $464.0M | $781.2M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.3B | $2.9B | ||
| Q2 25 | $1.2B | $2.9B | ||
| Q1 25 | $1.1B | $3.0B | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | $976.9M | $3.4B | ||
| Q2 24 | $914.1M | $3.4B | ||
| Q1 24 | $855.1M | $3.4B |
| Q4 25 | — | — | ||
| Q3 25 | — | 4.30× | ||
| Q2 25 | — | 3.97× | ||
| Q1 25 | — | 3.91× | ||
| Q4 24 | — | 3.85× | ||
| Q3 24 | — | 2.75× | ||
| Q2 24 | — | 2.67× | ||
| Q1 24 | — | 2.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-64.6M |
| Free Cash FlowOCF − Capex | — | $-70.7M |
| FCF MarginFCF / Revenue | — | -16.1% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $54.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | — | ||
| Q3 25 | $74.3M | $-64.6M | ||
| Q2 25 | $64.0M | $17.8M | ||
| Q1 25 | $20.3M | $52.7M | ||
| Q4 24 | $40.4M | $80.3M | ||
| Q3 24 | $63.2M | $4.2M | ||
| Q2 24 | $25.0M | $11.3M | ||
| Q1 24 | $29.1M | $35.1M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | $-70.7M | ||
| Q2 25 | — | $11.5M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | — | $71.7M | ||
| Q3 24 | $63.2M | $-679.0K | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $27.5M |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | -16.1% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 25.2% | -0.1% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 5.8% |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | 1.4% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | 63.17× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 0.56× | ||
| Q2 24 | 0.75× | 2.87× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
BGS
| Specialty Segment | $150.5M | 34% |
| Meals Segment | $110.0M | 25% |
| Spices And Flavor Solutions Segment | $101.4M | 23% |
| Frozen And Vegetables Segment | $77.4M | 18% |
